Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Cancer

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1739100

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1739100

Desmoid Tumors

PUBLISHED:
PAGES: 286 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Desmoid Tumors Market to Reach US$8.0 Billion by 2030

The global market for Desmoid Tumors estimated at US$5.6 Billion in the year 2024, is expected to reach US$8.0 Billion by 2030, growing at a CAGR of 6.2% over the analysis period 2024-2030. Non-steroidal Anti-inflammatory Drugs, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$3.0 Billion by the end of the analysis period. Growth in the Targeted Therapy segment is estimated at 7.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.5 Billion While China is Forecast to Grow at 9.9% CAGR

The Desmoid Tumors market in the U.S. is estimated at US$1.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 9.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.9% and 6.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.0% CAGR.

Global Desmoid Tumors Market - Key Trends & Drivers Summarized

What’s Fueling the Focus on Rare Tumors? A Strategic Look at the Desmoid Tumors Market

Desmoid tumors, also known as aggressive fibromatosis, are rare, non-metastasizing but locally invasive soft tissue tumors that present a complex clinical challenge due to their unpredictable progression and anatomical impact. Historically underdiagnosed and undertreated, this condition is now gaining renewed interest from both pharmaceutical innovators and clinical researchers due to advancements in genomic profiling and targeted therapies. One major trend reshaping the market is the identification of mutations in the CTNNB1 gene and the APC gene, which has opened the door to precision medicine approaches. These genetic markers allow stratification of patients for treatment responsiveness, particularly to Wnt/β-catenin signaling pathway inhibitors.

Another transformative trend is the shift away from surgery as the first line of treatment. Increasingly, physicians are adopting a “watchful waiting” strategy, supported by emerging data that many desmoid tumors stabilize or regress spontaneously. When intervention is necessary, non-surgical treatments including tyrosine kinase inhibitors (e.g., sorafenib) and gamma-secretase inhibitors (e.g., nirogacestat) are showing promising results. Regulatory momentum is also accelerating-U.S. FDA designations such as Orphan Drug Status and Fast Track designations for investigational therapies have attracted biotech investment into this rare disease space.

Why Is Treatment Modality Evolution So Critical in This Market?

The management paradigm for desmoid tumors is evolving rapidly, driven by the limitations of conventional surgery and radiotherapy, which carry high recurrence rates and morbidities. The newer treatment protocols are now favoring systemic therapies over localized interventions. Oral tyrosine kinase inhibitors (TKIs) like sorafenib, pazopanib, and imatinib are gaining traction for their non-invasive administration and relatively favorable safety profiles. These drugs inhibit angiogenesis and tumor proliferation pathways and have demonstrated effectiveness in delaying progression in unresectable cases.

Targeted therapies, particularly gamma-secretase inhibitors, represent a cutting-edge segment of the pipeline. SpringWorks Therapeutics' nirogacestat has emerged as a frontrunner after demonstrating statistically significant progression-free survival in phase III trials. These agents are poised to redefine standards of care as they interfere directly with the Notch signaling pathways implicated in tumor growth. Meanwhile, NSAIDs and hormonal therapies like tamoxifen continue to be used in select cases, particularly when systemic therapies are not tolerated. This therapeutic diversification is transforming the clinical outlook for desmoid tumor patients and expanding treatment options across disease stages and patient demographics.

Where Is Demand Emerging and Who Are the Key Stakeholders?

The desmoid tumor market is primarily concentrated in North America and Western Europe, where diagnostic infrastructure and rare disease research funding are most robust. However, rising awareness in emerging markets-particularly in urban hospital systems in Asia-Pacific and Latin America-is beginning to shift the global landscape. Diagnostic imaging improvements, increased physician education, and access to genomic testing are aiding earlier detection and more accurate classification of tumor subtypes.

Key stakeholders include academic research institutions, oncology-focused pharmaceutical companies, rare disease advocacy groups, and clinical trial networks. Patient registries and biobanking efforts are being expanded to better understand epidemiological patterns and treatment outcomes. Institutions like the Desmoid Tumor Research Foundation are playing a crucial role in uniting stakeholders and accelerating funding toward investigational therapies. Moreover, payer systems and health technology assessment (HTA) bodies are beginning to include desmoid tumor treatments in reimbursement discussions, especially for drugs with strong clinical trial data and orphan designations.

What’s Driving Growth in the Desmoid Tumors Therapeutics Market?

The growth in the desmoid tumors market is driven by several factors closely tied to therapeutic innovation, orphan drug development, and improved diagnostic capabilities. First, the emergence of precision therapies targeting molecular pathways such as β-catenin and Notch signaling has reinvigorated clinical R&D, attracting investment from niche oncology biotechs. The success of investigational therapies like nirogacestat, alongside repurposed oncology agents, is broadening treatment options for patients previously limited to invasive surgery or palliative care.

Second, the proliferation of genomic testing in oncology centers has improved mutation-based diagnosis, allowing earlier and more accurate identification of desmoid tumors and stratification for therapy selection. Moreover, patient advocacy and global rare disease coalitions are successfully lobbying for faster regulatory approvals, expanded compassionate use programs, and reimbursement pathways. The inclusion of desmoid tumors in rare cancer registries and global clinical trials is also boosting data collection, awareness, and clinical participation. These dynamics, combined with favorable regulatory designations and a high unmet medical need, are driving sustained growth and reshaping the commercial and clinical future of the desmoid tumor treatment landscape.

SCOPE OF STUDY:

The report analyzes the Desmoid Tumors market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy, Other Drug Types); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Retail Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

  • 180 Life Sciences
  • AFT Pharmaceuticals
  • Amgen
  • AstraZeneca
  • Ayala Pharmaceuticals
  • Bayer AG
  • Immunome, Inc.
  • Intas Pharmaceuticals
  • Iterion Therapeutics
  • Jina Pharmaceuticals
  • Johnson & Johnson
  • MedPact
  • Merck KGaA
  • Novartis
  • Pfizer
  • Recursion Pharmaceuticals, Inc.
  • Roche
  • SpringWorks Therapeutics, Inc.
  • Takeda Pharmaceutical Company
  • Timber Pharmaceuticals

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

Show more
Product Code: MCP33712

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Desmoid Tumors - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Awareness and Early Diagnosis of Rare Soft Tissue Tumors Expands Addressable Market for Desmoid Tumor Therapies
    • Increased Use of Imaging and Biopsy Tools Throws the Spotlight on Non-Invasive Diagnostic Advancements
    • Growing Pipeline of Targeted Therapies and Small Molecule Inhibitors Drives Innovation in Desmoid Tumor Management
    • Regulatory Approvals and Orphan Drug Designations Propel Investment in Desmoid Tumor Drug Development
    • Expansion of Clinical Trials Focused on Gamma Secretase Inhibitors Spurs Momentum in Targeted Treatment Options
    • Growing Role of Multidisciplinary Tumor Boards Strengthens Business Case for Personalized Therapy Strategies
    • Shift Toward Active Surveillance and Conservative Management in Select Cases Challenges Pharmaceutical Demand
    • Increased Genetic Screening for APC and CTNNB1 Mutations Enhances Precision Diagnosis and Therapeutic Targeting
    • AI-Enabled Diagnostic Imaging Tools Support Accurate and Early Detection, Expanding Treatment Opportunities
    • Rising Demand for Non-Surgical Therapies Spurs Adoption of Systemic and Minimally Invasive Options
    • Increased Incidence of Sporadic Desmoid Tumors in Younger Adults Expands Long-Term Treatment Horizons
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Desmoid Tumors Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Desmoid Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Desmoid Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Desmoid Tumors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Non-steroidal Anti-inflammatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Non-steroidal Anti-inflammatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Non-steroidal Anti-inflammatory Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hormone Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hormone Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Hormone Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Desmoid Tumors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • JAPAN
    • Desmoid Tumors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • CHINA
    • Desmoid Tumors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • EUROPE
    • Desmoid Tumors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Desmoid Tumors by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Desmoid Tumors by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Desmoid Tumors by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • FRANCE
    • Desmoid Tumors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: France 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • GERMANY
    • Desmoid Tumors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Germany 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Italy 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Desmoid Tumors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: UK 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Spain 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Spain 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Russia 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Russia 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Desmoid Tumors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Desmoid Tumors by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Desmoid Tumors by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Desmoid Tumors by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Desmoid Tumors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Australia 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Australia 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • INDIA
    • Desmoid Tumors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: India 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: India 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: South Korea 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: South Korea 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Desmoid Tumors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Desmoid Tumors by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Desmoid Tumors by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Desmoid Tumors by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Latin America 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Argentina 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Argentina 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Brazil 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Brazil 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Mexico 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Mexico 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Desmoid Tumors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Desmoid Tumors by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Desmoid Tumors by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Desmoid Tumors by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Middle East 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Iran 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Iran 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Israel 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Israel 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: UAE 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: UAE 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • AFRICA
    • Desmoid Tumors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Africa 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Africa 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!